LMT-28

Research use only, not for human use.

LMT-28 (LMT28) is a specific blocker of IL-6 signaling via inhibits IL-6Rβ (gp130) with IC50 of 5.9 uM (IL-6–induced luciferase activity).

LMT-28 (LMT28) is a specific blocker of IL-6 signaling via inhibits IL-6Rβ (gp130) with IC50 of 5.9 uM (IL-6–induced luciferase activity), selectively inhibits IL-6–induced phosphorylation of STAT3, JAK2, and gp130; does not affect LIF-induced STAT3 activation and not inhibit IL-11 stimulation on HepG2 cells; binds directly and specifically to gp130, and thereby inhibits the interaction of gp130 with the IL-6/IL-6Rα complex; inhibits IL-6–induced proliferation of the human erythroleukemic cell line TF-1 with IC50 of 7.5 uM; inhibits IL-6–induced TNF-α production, ameliorates the progression of pancreatitis in mice.

Cell Proliferation Assay Cell Line:TF-1 cells (1 ng/mL IL-6-induced)Concentration:1, 10, 100, 1000, 10000 nM Incubation Time:72 hours Result:Markedly inhibited IL-6–induced TF-1 proliferation with an IC50 value of 7.5 μM.Western Blot Analysis Cell Line:HepG2 cells (treated with 10 ng/mL IL-6) Concentration:1, 3, 10, 30, and 100 μM Incubation Time:1 hour Result:Inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130.

Animal Model:Six-week-old male DBA/1J mice (collagen-induced arthritis mice, CIA)Dosage:0-0.5 mg/kg Administration:Oral; once daily for 15 days Result:Markedly reduced the serum levels of cartilage oligomeric matrix protein (COMP) by 50%, serum amyloid P (SAP) by 55%, and anti-CII IgG by 62%.

C25H32F3N5O4

Apoptosis

IL Receptor

Interleukin Receptor

——

——

1239600-18-0

311.422

C17H29NO4

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (321.11 mM)

O=C1OC[C@H](C(C)C)N1C([C@@H](C)[C@H](O)C(CCCCC)=C)=O

(S)-3-((2S,3S)-3-hydroxy-2-methyl-4-methylenenonanoyl)-4-isopropyloxazolidin-2-one

(-20℃)

With Ice Pack

≥ 2 years